Title | Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. |
Publication Type | Journal Article |
Year of Publication | 2006 |
Authors | Friedland, Gerald, Saye Khoo, Christopher Jack, and Umesh Lalloo |
Journal | The Journal of antimicrobial chemotherapy |
Volume | 58 |
Issue | 6 |
Pagination | 1299-302 |
Date Published | 2006 Dec |
ISSN | 0305-7453 |
Keywords | Adult, Anti-HIV Agents, Antibiotics, Antitubercular, Benzoxazines, CD4 Lymphocyte Count, Chromatography, High Pressure Liquid, Didanosine, Drug Therapy, Combination, Female, HIV Infections, Humans, Lamivudine, Longitudinal Studies, Male, Oxazines, Rifampin, Treatment Outcome, Tuberculosis, Pulmonary, Viral Load |
Abstract | Pharmacokinetic interactions between rifampicin and antiretroviral therapy (ART), including efavirenz, are problematic and need to be better defined to determine proper dose and to be correlated with short-term and long-term clinical outcomes. |
DOI | 10.3109/00952990.2011.568081 |
Alternate Journal | J. Antimicrob. Chemother. |